Elevance Health Q3 2026: EPS beat, guidance raised, margins thin
Elevance beat on the bottom line and raised its 2026 outlook, but the quarter's profit leaned on investment income as much as on insurance operations. GAAP EPS of $6.27 topped the $4.73 consensus, and adjusted EPS rose to $6.99 from $6.03. Read the rest with that split in mind: Carelon carried the operating gain while Health Benefits margin thinned to 1.0%.
1 · Expected vs. Actual
Free preview belowGAAP EPS of $6.27 beat the $4.73 consensus, and adjusted EPS of $6.99 was up 15.9% from $6.03. Those figures include a net non-operating benefit of $1.85 per share, alongside the $1.04 billion of net investment income. Strip that out and the operating story is thinner: total operating gain fell 2.0% to $1.27 billion.
Operating revenue rose 0.7% to $50.44 billion from $50.09 billion, but premiums actually slipped 0.2% to $41.70 billion. Growth came from product revenue, up 4.8% to $6.45 billion, and service fees, up 6.8% to $2.28 billion. Total revenue of $51.43 billion also included $1.04 billion of net investment income, up 65.9%.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-10-21
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.